For parents of myopic children, pediatric ophthalmologists, and optometrists, the challenge of slowing the rapid progression of childhood myopia (short-sightedness) that leads to high myopia (greater than minus 6 diopters) and increased lifelong risks of retinal detachment, glaucoma, cataracts, and myopic maculopathy remains critical. Conventional single-vision spectacles and contact lenses correct distance vision but do not address the underlying mechanism of axial elongation (eye growth), allowing myopia to worsen by approximately minus 0.50 to minus 1.00 diopter per year in children. The defocus incorporated soft contact (DISC) lens directly addresses this treatment gap as a multi-zone soft contact lens that simultaneously provides clear distance vision (central zone) and a myopic defocused (blurred) image on the peripheral retina (surrounding concentric rings), sending a biochemical STOP signal that inhibits axial elongation—the anatomical driver of progressive myopia. Developed by PolyU research team and clinically validated, DISC lenses have demonstrated reduction of myopia progression by 40 to 60 percent compared to single-vision lenses in clinical trials. Global Leading Market Research Publisher QYResearch announces the release of its latest report *“Defocus Incorporated Soft Contact (DISC) Lens - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”*. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Defocus Incorporated Soft Contact (DISC) Lens market, including market size, share, demand, industry development status, and forecasts for the next few years. The global market for Defocus Incorporated Soft Contact (DISC) Lens was estimated to be worth USD 157 million in 2024 and is forecast to a readjusted size of USD 442 million by 2031 with a CAGR of 15.3 percent during the forecast period 2025-2031. Defocus incorporated soft contact (DISC) lens is a multi-zone soft contact lens that slows myopia (short-sightedness) progression by simultaneously providing clear distance vision and a myopic (blurred) image on the retina in the periphery. Developed by a PolyU research team, this innovative lens uses a concentric ring design (typically 5 to 9 alternating zones of distance correction and defocus power) to send a STOP signal to the eye, inhibiting the axial elongation that causes myopia to worsen in children and adolescents. 【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】 https://www.qyresearch.com/reports/5056265/defocus-incorporated-soft-contact--disc--lens 1. Product Design and Clinical Mechanism In 2024, global DISC lens production reached approximately 12.08 million pieces, with an average global market price of approximately USD 3.50 to 6.00 per lens depending on replacement schedule (daily, bi-weekly, monthly). This product typically has a single-line production capacity of approximately 500,000 to 1,000,000 units, with an industry gross profit margin of approximately 20 to 40 percent (higher for proprietary designs and daily disposables, lower for monthly replacement and licensed manufacturers). Raw materials account for the largest portion of costs (30 to 50 percent), including high-purity monomers (hydroxyethyl methacrylate HEMA, silicone macromers for silicone hydrogel versions), functional additives (UV blockers, wetting agents, oxygen permeability enhancers), and packaging materials (blister packs, foil seals). Equipment depreciation and manufacturing/labor costs account for 20 to 35 percent (precision molding, lens inspection, hydration, sterilization via autoclave). The DISC lens design (also known as MiSight by CooperVision, the leading commercialized version) features a concentric ring alternating between distance correction (central 3 to 4 millimeter zone) and treatment zones providing peripheral myopic defocus (plus 2.00 to plus 4.00 diopters relative to distance power). When light passes through treatment zones, it focuses in front of the peripheral retina (myopic defocus), creating a signal that slows axial elongation by approximately 0.10 to 0.20 millimeters per year—translating to approximately minus 0.25 to minus 0.50 diopter slower progression annually. Clinical trials (CooperVision MiSight phase 3, 3-year data, published 2020) showed 59 percent reduction in myopia progression (spherical equivalent refraction) and 52 percent reduction in axial elongation compared to single-vision control lenses. Extended 6-year data shows continued efficacy with no rebound upon cessation. 2. Replacement Schedules and Patient Segmentation The DISC lens market segments by recommended replacement schedule into daily disposables, bi-weekly disposables, and monthly disposables. Daily disposable DISC lenses represent the fastest-growing segment (CAGR 18 to 20 percent), accounting for approximately 45 to 50 percent of unit volume, driven by pediatric safety advantages (no cleaning, disinfection, or case hygiene required, reducing risk of microbial keratitis by 50 to 75 percent versus reusable lenses), convenience for busy parents (no nightly lens care routines), and favorable reimbursement (many vision plans waive copay for daily disposable myopia management lenses in children). Daily lenses priced at USD 1.50 to 3.00 per pair per day (USD 500 to 1,100 annually). Bi-weekly DISC lenses (replace every 2 weeks) account for approximately 25 to 30 percent of unit volume, lower annual cost (USD 400 to 800) but require patient compliance with cleaning and disinfection (multipurpose solution or hydrogen peroxide systems). Bi-weekly lenses often prescribed for older children (10 to 15 years) or those who have successfully demonstrated compliance with soft contact lens hygiene. Monthly DISC lenses (replace every 30 days) represent 20 to 25 percent of volume, lowest annual cost (USD 300 to 600) but highest compliance burden and infection risk; primarily prescribed for older teenagers (15 to 18 years) or existing contact lens wearers transitioning to myopia management lenses. By age group, children (ages 6 to 12 years) represent the largest and most important segment, accounting for approximately 60 to 65 percent of DISC lens fits, as treatment initiated at younger ages captures greater cumulative benefit (each year of slowed progression reduces final myopia by approximately minus 0.25 to minus 0.50 diopters). FDA approval for CooperVision MiSight extends down to age 8 years, with off-label use as young as 6 years common outside US. Teenagers (ages 13 to 17 years) account for 30 to 35 percent of fits, still benefiting (axial elongation continues through age 18 to 21 years) but with smaller absolute treatment effect (older children have slower baseline progression, approximately minus 0.30 to minus 0.50 diopter annual versus minus 0.50 to minus 1.00 in younger children). 3. Competitive Landscape and Regional Adoption The DISC lens market features moderate concentration with global contact lens leaders and emerging regional specialists. Leading players include CooperVision (US subsidiary of CooperCompanies, global market leader with approximately 55 to 60 percent share of commercial DISC lens market through MiSight brand (FDA approved, CE marked, Chinese NMPA registered)), Johnson & Johnson Vision Care (US, approximately 10 to 12 percent share with ACUVUE Abiliti (myopia management lens family, including DISC-equivalent design plus soft bifocal designs)), SEED (Japan, approximately 8 to 10 percent share, SEED 1-Day Myopia Control Lens (disc design) dominant in Japanese market), Markennovy (Spain, 5 to 7 percent share, European regional leader), Zhuhai Boai Zhiguang Technology (China, 5 to 7 percent, domestic Chinese DISC lens manufacturer leveraging academic research), Visioneering Technologies (Australia, 4 to 6 percent, NaturalVue Multifocal used off-label for myopia control), Unicon Optical (Taiwan, 3 to 5 percent OEM manufacturer for regional brands), Bio Thin (South Korea, 2 to 4 percent), Eyebright Medical (China, 2 to 3 percent), Autek (China, 2 to 3 percent), Safilens (Italy, 2 to 3 percent), SwissLens (Switzerland, 1 to 2 percent). CooperVision dominates due to first-mover advantage (FDA approval 2019, extensive clinical trial data, professional education programs, parent marketing campaigns), though generic and regional brands offer lower-cost alternatives (USD 1.00 to 2.00 per lens versus USD 1.50 to 3.00 for MiSight) capturing price-sensitive markets. Geographic market distribution shows Asia-Pacific leading with approximately 45 to 50 percent of global DISC lens consumption (China largest single market (25 to 30 percent of global), Japan, South Korea, Taiwan, Australia high myopia prevalence, strong parent demand for interventions). North America (United States primarily) represents 25 to 30 percent (FDA-approved MiSight dominates, modest myopia prevalence versus Asia but high per-capita spending). Europe represents 20 to 25 percent (Germany, France, UK, Nordic countries leaders), and rest of world 3 to 5 percent. Asia-Pacific is projected to reach 55 to 60 percent by 2031, driven by escalating myopia epidemic (80 to 90 percent of teenagers myopic in urban East Asia, up from 20 to 30 percent in 1950s). 4. Technical and Clinical Challenges Three challenges dominate DISC lens adoption. First, treatment efficacy variability—approximately 5 to 10 percent of children show minimal response (less than 0.10 millimeter axial elongation reduction) despite good lens wear; no validated predictors of response currently available. New optical coherence tomography-based algorithms (under development, CooperVision, expected 2027) may identify peripheral retinal shape phenotypes that predict strong responders. Second, compliance with wear schedule—optimal efficacy requires 6 to 7 days per week, 10 to 12 hours per day; intermittent wear reduces signal strength. Digital reminders (smartphone apps linked to practice management software) have improved adherence by 25 to 30 percent. Third, educator and parent awareness—DISC lenses compete with orthokeratology (hard lenses worn overnight, similar efficacy, higher infection risk, FDA approved but requires fitting) and low-dose atropine eye drops (pharmaceutical, nightly drops, no vision correction provided). Clinical consensus (International Myopia Institute, updated 2026 guidelines) recommends all three modalities as first-line, with DISC lenses preferred for children who want daytime correction, participate in sports/swimming, and whose parents prioritize convenience. 5. Recent User Case Example (Six-Month Window) A pediatric optometry practice in Shanghai (4 locations, 12 optometrists, 8,000 pediatric patients annually) faced myopia progression rates consistently above national average (patients progressing by minus 0.70 diopter annually despite single-vision distance correction). From November 2025 to April 2026, the practice implemented DISC lens protocol for 450 children (ages 8 to 12 years, baseline myopia minus 1.50 to minus 4.00 diopters). Daily disposable DISC lenses prescribed (CooperVision MiSight). Results over six months: mean axial elongation 0.09 millimeters (estimated annualized 0.18 millimeters) versus historical control 0.15 millimeters over six months (annualized 0.30 millimeters), representing 40 percent slowing of myopia progression. Parent satisfaction surveys (n equals 380) reported 91 percent satisfied or very satisfied, 88 percent reporting child adapted within 3 days, zero cases of contact lens-related adverse events (no corneal infiltrative events, no microbial keratitis). The practice added two additional optometrists to manage DISC lens fits, projecting 1,200 fits in 2026. 6. Original Observation: Silicone Hydrogel DISC Lenses An exclusive trend identified in this analysis is the shift from conventional hydrogel DISC lenses (50 to 80 Dk/t, low oxygen permeability, limiting safe wear time) to silicone hydrogel DISC lenses (100 to 150 Dk/t). Higher oxygen permeability reduces hypoxia-related complications (corneal edema, neovascularization, limbal redness), enabling extended daily wear (14 to 16 hours) and providing theoretical safety margin for children. CooperVision‘s MiSight 1-day is available in conventional hydrogel, but next-generation silicone hydrogel MiSight is expected 2027. Johnson & Johnson‘s Abiliti offers silicone hydrogel version in some markets. By 2028, silicone hydrogel DISC lenses projected to capture 40 to 50 percent of market (USD 175 to 220 million), shifting industry conversation from safety equivalence to orthokeratology to safety superiority (higher oxygen transmissibility than ortho-k, which covers cornea overnight). A secondary exclusive observation concerns expanded indications for disc lenses in pre-myopia (children with low hyperopia or plano who are at high risk of progressing due to family history, near work load). No DISC lens is currently labeled for prevention of myopia onset; off-label treatment proving successful in small pilot studies. If FDA expands label (potentially with 5-year prevention trial results), addressable market would more than double, adding children ages 4 to 7 years. 7. Report Value Summary For myopia management clinicians, optometric practice owners, and vision care investors, the full report provides quantitative market forecasts by region (Asia-Pacific, North America, Europe, Rest of World), replacement schedule (daily, bi-weekly, monthly), age group (children (6 to 12 years), teenager (13 to 17 years)), and material type (conventional hydrogel, silicone hydrogel). It includes competitive market share rankings, technology assessments of disc lens designs and manufacturing methods (cast molding versus lathe cutting), pricing analysis by replacement schedule and geography, and a regulatory tracking dashboard covering FDA approved indications, CE mark under Medical Device Regulation (MDR), Chinese NMPA approvals, and clinical practice guidelines from American Academy of Ophthalmology, European Academy of Optometry, International Myopia Institute. Contact Us: If you have any queries regarding this report or if you would like further information, please contact us: QY Research Inc. Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States EN: https://www.qyresearch.com E-mail: global@qyresearch.com Tel: 001-626-842-1666(US) JP: https://www.qyresearch.co.jp